References
- Rhodus NL, Kerr AR, Patel K. Oral cancer: leukoplakia, premalignancy, and squamous cell carcinoma. Dent Clin North Am. 2014;58(2):315-40.
- Elango JK, Gangadharan P, Sumithra S, Kuriakose MA. Trends of head and neck cancers in urban and rural India. Asian Pac J Cancer Prev. 2006;7(1):108-12.
- Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. CA Cancer J Clin. 2008;58(2):71-96.
- De Vries N, van der Waal I, Snow GB. Multiple primary tumours in oral cancer. Int J Oral Maxillofac Surg 1986;15(1):85–7.
- Leon X, Quer M, Diez S, Orus C, Lopez-Pousa A, Burgues J. Second neoplasm in patients with head and neck cancer. Head Neck 1999;21(3):204–10.
- Lippman SM, Hawk ET. Cancer prevention: from 1727 to milestones of the past 100 years. Cancer Res 2009;69(13):5269-84.
- Braakhuis BJ, Brakenhoff RH, Leemans CR. Second field tumors: a new opportunity for cancer prevention? Oncologist 2005;10(7):493-500.
- Kuriakose MA, Sharan R. Oral Cancer Prevention. Oral Maxillofac Surg Clin N Am. 2006;18(4):493–511.
- Hasina R, Lingen MW. Angiogenesis in Oral Cancer. J Dent Educ. 2001;65(11): 1282-90
- Iype EM, Pandey M, Mathew A, Thomas G, Sebastian P, Nair MK. Oral cancer among patients under the age of 35 years. J Postgrad Med 2001;47(3):171.
- Dahlstrom KR, Little JA, Zafereo ME, Lung M, Wei Q, Sturgis EM. Squamous cell carcinoma of the head and neck in never smoker-never drinkers: a descriptive epidemiologic study. Head Neck 2008;30(1):75–84.
- Lucenteforte E, Garavello W, Bosetti C, La Vecchi C. Dietary factors and oral and pharyngeal cancer risk. Oral Oncol 2009;45(6):461–67.
- Lindsay C, Seikaly H, Biron VL. Epigenetics of oropharyngeal squamous cell carcinoma: opportunities for novel chemotherapeutic targets. Journal of otolaryngology - head & neck surgery. 2017;46(1):9-9.
- Govindarajan R, Siegel ER, Simmons DL, Lang NP. Thiazolidinedione (TZD) exposure and risk of squamous cell carcinoma of head and neck (SCCHN). 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25 (18_suppl):1511.
- Suvarna C, Chaitanya NC, Ameer S, Inamdar P, Alugubelli S, Bhagyanagar A. Chemopreventive agents in oral premalignancy: A medical management review. Journal of International Society of Preventive & Community Dentistry. 2020 Mar;10(2):127.
- Siemianowicz K, Likus W, Dorecka M, Wilk R, Dziubdziela W, Markowski J. Chemoprevention of Head and Neck Cancers: Does It Have Only One Face?. BioMed Res Int. 2018 Sep 25;2018.
- Nadeau C, Kerr AR. Evaluation and management of oral potentially malignant disorders. Dental Clinics. 2018 Jan 1;62(1):1-27.
- Piattelli A, Fioroni M, Santinelli A, Rubini C. bcl-2 expression and apoptotic bodies in 13-cis-retinoic acid (isotretinoin)-topically treated oral leukoplakia: a pilot study. Oral Oncol. 1999 May 1;35(3):314-20.
- Tsao AS, Liu D, Martin J, Tang XM, Lee JJ, El-Naggar AK, Wistuba I, Culotta KS, Mao L, Gillenwater A, Sagesaka YM. Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res. 2009 Nov;2(11):931-41.
- Armstrong WB, Kennedy AR, Wan XS, Atiba J, McLaren CE, Meyskens FL. Single-dose administration of Bowman-Birk inhibitor concentrate in patients with oral leukoplakia. Cancer Epidemiol Prev Biomarkers. 2000 Jan 1;9(1):43-7.
- Armstrong WB, Taylor TH, Kennedy AR, Melrose RJ, Messadi DV, Gu M, Le AD, Perloff M, Civantos F, Goodwin WJ, Wirth LJ. Bowman birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial. Cancer Prev Res. 2013 May;6(5):410-8.
- Mallery SR, Tong M, Shumway BS, Curran AE, Larsen PE, Ness GM, Kennedy KS, Blakey GH, Kushner GM, Vickers AM, Han B. Topical application of a mucoadhesive freeze-dried black raspberry gel induces clinical and histologic regression and reduces loss of heterozygosity events in premalignant oral intraepithelial lesions: results from a multicentered, placebo-controlled clinical trial. Clin Cancer Res. 2014 Apr 1;20(7):1910-24.
- Epstein JB, Wong FL, Millner A, Le ND. Topical bleomycin treatment of oral leukoplakia: a randomized double-blind clinical trial. Head & neck. 1994 Nov;16(6):539-44.
- Mak MP, William Jr WN. Targeting the epidermal growth factor receptor for head and neck cancer chemoprevention. Oral Oncol. 2014 Oct 1;50(10):918-23z.
- Galli A, Mello T, Ceni E, Surrenti E, Surrenti C. The potential of antidiabetic thiazolidinediones for anticancer therapy. Expert Opin Investig Drugs. 2006 Sep 1;15(9):1039-49.
- Papadimitrakopoulou VA, William WN, Dannenberg AJ, Lippman SM, Lee JJ, Ondrey FG, et al. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clin Cancer Res 2008;14(7):2095–101.
- Behura SS, Singh DK, Masthan KM, Babu NA, Sah S. Chemoprevention of oral cancer: A promising venture. Int J Oral Care Res. 2015;3(2):80-7.
- Sun SY, Lotan R. Retinoids and their receptors in cancer development and chemoprevention. Crit Rev Oncol Hematol 2002;41(1):41 – 55.
- Hong WK, Endicott J, Itri LM, Doos W, Batsakis JG, Bell R, et al. 13-cisretinoic acid in the treatment of oral leukoplakia. N Engl J Med 1986; 315(24):1501–5.
- Papadimitrakopoulou VA, Clayman GL, Shin DM, Myers JN, Gillenwater AM, Goepfert H, et al. Biochemoprevention for dysplastic lesions of the upper aerodigestive tract. Arch Otolaryngol Head Neck Surg 1999;125(10):1083–9.
- Shin DM, Khuri FR, Murphy B, Garden AS, Clayman G, Francisco M, et al. Combined interfereone alpha, 13-cis-retinoic acid, and alpha tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. J Clin Oncol 2001; 19(2):3010–7.
- Mao L, Papadimitrakopoulou V, Shin DM, Fan Y, Zhou X, Lee JS, et al. Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy. J Natl Cancer Inst. 1998; 90(20):1545–51.
- Nagao T, Warnakulasuriya S, Nakamura T, Kato S, Yamamoto K, Fukano H, et al. Treatment of oral leukoplakia with a low dose of beta-carotene and vitamin C supplements: A randomized controlled trial. Int J Cancer. 2015;136(7):1708-17.
- Mulshine JL, Atkinson JC, Greer RO, Papadimitrakopoulou VA, Van Waes C, Rudy S, et al. Randomized, double-blind, placebo controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clin Cancer Res 2004; 10(5):1565–73.
- Normanno N, Bianco C, Strizzi L, Mancino M, Maiello MR, De Luca A, et al. The ErbB receptors and their ligands in cancer: an overview. Curr Drug Targets 2005;6(3): 243–57.
- William WN, Papadimitrakopoulou V, Lee JJ, Mao L, Cohen EE, Lin HY. Erlotinib and the Risk of oral cancer: the erlotinib prevention of oral cancer (EPOC) randomized clinical trial. JAMA Oncol 2016;2(2):209-16.
- Saba NF, Hurwitz SJ, Kono SA, Yang CS, Zhao Y, Chen Z, et al. Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase 1b and pharmacokinetic study. Cancer prev Res (Phila) 2014;7(3):283–91.
- Rudin CM, Cohen EE, Papadimitrakopoulou VA, Silverman S, Recant W, El-Naggar AK, et al. An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. J Clin Oncol 2003; 21(24): 4546–52.
- Li Y, Li LJ, Zhang ST, Wang LJ, Zhang Z, Gao N, et al. In vitro and clinical studies of gene therapy with recombinant human adenovirus-p53 injection for oral leukoplakia. Clin Cancer Res 2009;15(21):6724–31.
- Rhodus N, Rohrer M, Pambuccian S, Keel S, Bliss R, Szabo E. Phase IIa Chemoprevention Clinical Trial of Pioglitazone for Oral Leukoplakia. J Dent Res 2011; 90(A) [abstract].
- Rosas RR, Nachbor KM, Handley N, Mathison G, Wuertz BR, Ba’th F, Ondrey FG. Preclinical evidence for pioglitazone and bexarotene combination in oral cancer chemoprevention. Head & neck. 2022 Mar;44(3):661-71.
- Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001;21(2895):e2900.
- Tsao AS, Liu D, Martin J, Tang XM, Lee JJ, El-Naggar AK, et al. Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila). 2009;2(11):931–41.
- Kerr AR, Lodi G. Management of oral potentially malignant disorders. Oral Diseases. 2021;27(8):2008-25.
- Saba NF, Haigentz M, Vermorken JB, Strojan P, Bossi P, Rinaldo A, et al. Prevention of head and neck squamous cell carcinoma: Removing the “chemo” from “chemoprevention”. Oral Oncol. 2015;51(2):112-18.
- Foy JP, Bertolus C, William WN Jr, Saintigny P. Oral premalignancy: the roles of early detection and chemoprevention. Otolaryngol Clin North Am. 2013;46(4):579-97.
- Nandini DB, Rao RS, Deepak BS, Reddy PB. Sulforaphane in broccoli: The green chemoprevention!! Role in cancer prevention and therapy. Journal of Oral and Maxillofacial Pathology: JOMFP. 2020;24(2):405.
- Nagini S, Letchoumy PV, Thangavelu A, Ramachandran CR. Humans and hamsters: A comparative evaluation of carcinogen activation, DNA damage, cell proliferation, apoptosis, invasion, and angiogenesis in oral cancer patients and hamster buccal pouch carcinomas. Oral Oncol 2009;45(6): e31-7
- William WN, Papadimitrakopoulou VA. Optimizing biomarkers and endpoints in oral cancer chemoprevention trials Cancer Prev Res (Phila). 2013;6(5):375-8.
- Wu X, Desai KG, Mallery SR, Holpuch AS, Phelps MP, Schwendeman SP. Mucoadhesive fenretinide patches for site-specific chemoprevention of oral cancer: enhancement of oral mucosal permeation of fenretinide by coincorporation of propylene glycol and menthol. Mol Pharm. 2012;9(4):937-45.
- Bansal SS, Goel M, Aqil F, Vadhanam MV, Gupta RC. Advanced Drug Delivery Systems of Curcumin for Cancer Chemoprevention. Cancer Prev Res (Phila) 2011; 4(8):1158–71.
- Habibi N, Bissonnette C, Pei P, Wang D, Chang A, Raymond JE, Lahann J, Mallery SR. Mucopenetrating Janus Nanoparticles For Field-Coverage Oral Cancer Chemoprevention. Pharmaceutical Research. 2023;12:1-6.
- Martinez VD, MacAulay CE, Guillaud M, Lam WL, Zhang L, Corbett KK, et al. Targeting of chemoprevention to high-risk potentially malignant oral lesions: Challenges and opportunities. Oral Oncol. 2014;50(12):1123-30.